Matches in SemOpenAlex for { <https://semopenalex.org/work/W1621456877> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W1621456877 endingPage "92" @default.
- W1621456877 startingPage "7086" @default.
- W1621456877 abstract "We have evaluated immunohistochemical characteristics of tumors and the infiltrating cells in patients treated with various immunotherapy regimens. Forty-eight patients with advanced malignancies were treated with high dose i.v. recombinant interleukin-2 alone or in combination with cyclophosphamide, recombinant tumor necrosis factor, recombinant interferon-alpha, antimelanoma antibody 9.2.27, adoptively transferred tumor infiltrating lymphocytes, or lymphokine-activated killer cells. Thirty-four patients with metastatic melanoma and two patients with breast carcinoma underwent excision of one or more s.c. metastases either before, during, or after treatment. Twelve patients with metastatic renal cell carcinoma underwent pretreatment nephrectomy and these tumors were also studied. Tumor cells were evaluated for class I (HLA-A,B,C) and II (HLA-DR) antigen expression and the mononuclear infiltrate was characterized using an avidin-biotin immunoperoxidase technique. All melanomas were class I antigen positive. Fifty-three % of biopsied metastatic melanoma lesions, 58% of primary renal cell carcinomas, and neither of the two breast carcinomas expressed class II antigen prior to therapy. The pretreatment expression of class II antigens by a tumor was not predictive of a clinical response to recombinant interleukin 2-based therapy. After treatment, however, seven of seven biopsied regressing individual metastases intensely expressed DR antigen on over fifty percent of the cells while only three of ten nonresponding lesions did so. Regressing lesions were permeated with macrophages and both CD4 and CD8 T-cell subsets. There were no CD1 or NKH-1 positive infiltrating cells detected in any lesion. The response to recombinant interleukin 2-based immunotherapy is associated with T-cell as well as macrophage infiltration. DR antigen expression by tumor cells and T-cell infiltrate appear in individual lesions to be associated with this response." @default.
- W1621456877 created "2016-06-24" @default.
- W1621456877 creator A5012925206 @default.
- W1621456877 creator A5024528047 @default.
- W1621456877 creator A5035662199 @default.
- W1621456877 creator A5072133376 @default.
- W1621456877 date "1989-12-15" @default.
- W1621456877 modified "2023-09-27" @default.
- W1621456877 title "Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans." @default.
- W1621456877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2582450" @default.
- W1621456877 hasPublicationYear "1989" @default.
- W1621456877 type Work @default.
- W1621456877 sameAs 1621456877 @default.
- W1621456877 citedByCount "62" @default.
- W1621456877 countsByYear W16214568772018 @default.
- W1621456877 crossrefType "journal-article" @default.
- W1621456877 hasAuthorship W1621456877A5012925206 @default.
- W1621456877 hasAuthorship W1621456877A5024528047 @default.
- W1621456877 hasAuthorship W1621456877A5035662199 @default.
- W1621456877 hasAuthorship W1621456877A5072133376 @default.
- W1621456877 hasConcept C142724271 @default.
- W1621456877 hasConcept C147483822 @default.
- W1621456877 hasConcept C167672396 @default.
- W1621456877 hasConcept C203014093 @default.
- W1621456877 hasConcept C2777371288 @default.
- W1621456877 hasConcept C2777472916 @default.
- W1621456877 hasConcept C2777658100 @default.
- W1621456877 hasConcept C2777701055 @default.
- W1621456877 hasConcept C2778326572 @default.
- W1621456877 hasConcept C2778690821 @default.
- W1621456877 hasConcept C502942594 @default.
- W1621456877 hasConcept C71924100 @default.
- W1621456877 hasConcept C8891405 @default.
- W1621456877 hasConceptScore W1621456877C142724271 @default.
- W1621456877 hasConceptScore W1621456877C147483822 @default.
- W1621456877 hasConceptScore W1621456877C167672396 @default.
- W1621456877 hasConceptScore W1621456877C203014093 @default.
- W1621456877 hasConceptScore W1621456877C2777371288 @default.
- W1621456877 hasConceptScore W1621456877C2777472916 @default.
- W1621456877 hasConceptScore W1621456877C2777658100 @default.
- W1621456877 hasConceptScore W1621456877C2777701055 @default.
- W1621456877 hasConceptScore W1621456877C2778326572 @default.
- W1621456877 hasConceptScore W1621456877C2778690821 @default.
- W1621456877 hasConceptScore W1621456877C502942594 @default.
- W1621456877 hasConceptScore W1621456877C71924100 @default.
- W1621456877 hasConceptScore W1621456877C8891405 @default.
- W1621456877 hasIssue "24 Pt 1" @default.
- W1621456877 hasLocation W16214568771 @default.
- W1621456877 hasOpenAccess W1621456877 @default.
- W1621456877 hasPrimaryLocation W16214568771 @default.
- W1621456877 hasRelatedWork W1621456877 @default.
- W1621456877 hasRelatedWork W1987151488 @default.
- W1621456877 hasRelatedWork W2012340028 @default.
- W1621456877 hasRelatedWork W2044512220 @default.
- W1621456877 hasRelatedWork W2063379782 @default.
- W1621456877 hasRelatedWork W2082068809 @default.
- W1621456877 hasRelatedWork W2089196801 @default.
- W1621456877 hasRelatedWork W2140330161 @default.
- W1621456877 hasRelatedWork W2328036837 @default.
- W1621456877 hasRelatedWork W2410339616 @default.
- W1621456877 hasVolume "49" @default.
- W1621456877 isParatext "false" @default.
- W1621456877 isRetracted "false" @default.
- W1621456877 magId "1621456877" @default.
- W1621456877 workType "article" @default.